Jaka jest cena za Metagenomi, Inc. Common Stock (MGX)

Cena za Metagenomi, Inc. Common Stock (MGX) wynosi $1.21

Jaka jest kapitalizacja rynkowa dla Metagenomi, Inc. Common Stock (MGX)

Kapitalizacja rynkowa dla Metagenomi, Inc. Common Stock (MGX) wynosi $45.55M

Metagenomi, Inc. Common Stock (MGX) Wskaźnik C/WK

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

Rok	Wskaźnik P/B	Zmień
Za mało danych dla podanych dat.

Rok

Wskaźnik P/B

Zmień

Za mało danych dla podanych dat.

Firma	Wskaźnik P/B	Różnica wskaźnika P/B	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	3.7087	-	US

Firma

Wskaźnik P/B

Różnica wskaźnika P/B

Kraj